Pediatric Pulmonary Hypertension: A Systematic Approach
Abstract
Background: Pediatric pulmonary hypertension comprises a variety of etiologies across different age groups, requiring a systematic approach to diagnosis in children.
Case summary: A 7-year-old boy with nonverbal autism, oral aversion, and resolved muscular ventricular septal defect presented with heart failure and was found to have severe pulmonary hypertension. The initial diagnosis and treatment course was altered after a misleading cause, and he was ultimately found to have undetectable vitamin C levels. After repletion, he was weaned off pulmonary hypertension therapy and received nutritional supplementation via a gastrotomy tube.
Discussion: Chronic vitamin C deficiency can lead to pulmonary hypertension, and pediatric patients with neurodevelopmental disorders are at a higher risk of developing nutritional deficiencies.
Take-home message: This case emphasizes the importance of having a broad differential for pulmonary hypertension, with a systematic approach to thinking beyond congenital heart disease-related, autoimmune-related, and idiopathic pulmonary hypertension in children.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.